Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20,485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1.
Goss CH, Jain R, Seibold W, Picard AC, Hsu MC, Gupta A, Fajac I. Goss CH, et al. Among authors: gupta a. ERJ Open Res. 2020 Dec 7;6(4):00395-2020. doi: 10.1183/23120541.00395-2020. eCollection 2020 Oct. ERJ Open Res. 2020. PMID: 33313307 Free PMC article.
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers.
Gress C, Vogel-Claussen J, Badorrek P, Müller M, Hohl K, Konietzke M, Litzenburger T, Seibold W, Gupta A, Hohlfeld JM. Gress C, et al. Among authors: gupta a. Pulm Pharmacol Ther. 2023 Oct;82:102246. doi: 10.1016/j.pupt.2023.102246. Epub 2023 Aug 9. Pulm Pharmacol Ther. 2023. PMID: 37562641 Clinical Trial.
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study.
Chalmers JD, Shteinberg M, Mall MA, O'Donnell AE, Watz H, Gupta A, Frahm E, Eleftheraki A, Rauch J, Chotirmall SH, Armstrong AW, Eickholz P, Hasegawa N, Sauter W, McShane PJ. Chalmers JD, et al. Among authors: gupta a. Eur Respir J. 2024 Oct 28:2401551. doi: 10.1183/13993003.01551-2024. Online ahead of print. Eur Respir J. 2024. PMID: 39255990 Free article.
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment.
Hall IP, Fowler AV, Gupta A, Tetzlaff K, Nivens MC, Sarno M, Finnigan HA, Bateman ED, Rand Sutherland E. Hall IP, et al. Among authors: gupta a. Pulm Pharmacol Ther. 2015 Jun;32:37-44. doi: 10.1016/j.pupt.2015.03.003. Epub 2015 Apr 8. Pulm Pharmacol Ther. 2015. PMID: 25861737 Free article. Clinical Trial.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A, Koenen R, Hilbert J, Blatchford J, Kappeler D, Benediktus E, Wood C, Gupta A. Fowler A, et al. Among authors: gupta a. J Clin Pharmacol. 2017 Nov;57(11):1444-1453. doi: 10.1002/jcph.947. Epub 2017 Jun 13. J Clin Pharmacol. 2017. PMID: 28609567 Clinical Trial.
A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf.
Chalmers JD, Gupta A, Chotirmall SH, Armstrong A, Eickholz P, Hasegawa N, McShane PJ, O'Donnell AE, Shteinberg M, Watz H, Eleftheraki A, Diefenbach C, Sauter W. Chalmers JD, et al. Among authors: gupta a. ERJ Open Res. 2023 Jun 26;9(3):00633-2022. doi: 10.1183/23120541.00633-2022. eCollection 2023 May. ERJ Open Res. 2023. PMID: 37465817 Free PMC article.
20,485 results
You have reached the last available page of results. Please see the User Guide for more information.